Stock PHARM PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pharming Group N.V.

Equities

PHARM

NL0010391025

Market Closed - Euronext Amsterdam
Other stock markets
 16:35:00 26/04/2024 BST 		5-day change 1st Jan Change
0.9 EUR +2.16% Intraday chart for Pharming Group N.V. +2.16% -12.71%
04-22 Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
04-18 Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMING GROUP N.V. Stock Pharming Group N.V.
-12.71% 647M
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. Ratings Pharming Group N.V.